Lenalidomide in non-Hodgkin lymphoma: Biological perspectives and therapeutic opportunities

Athena Kritharis, Michael Coyle, Jaya Sharma, Andrew M. Evens

Research output: Contribution to journalArticlepeer-review

39 Scopus citations


Lenalidomide is an immunomodulatory drug (IMiD) with activity in lymphoid malignancies occurring primarily through immune modulation (eg, T-cell immune synapse enhancement and NK-cell/T-cell effector augmentation) and antiproliferative effects. Food and Drug Administration-approved for bortezomib-resistant, relapsed/refractory mantle-cell lymphoma, lenalidomide has demonstrated efficacy in several additional lymphoma subtypes. There are many ongoing clinical trials examining the use of lenalidomide alone or in combinatorial therapy. It will be important in these studies to delineate reliable, predictive biomarkers to optimally integrate lenalidomide into lymphoma treatment paradigms.

Original languageEnglish (US)
Pages (from-to)2471-2476
Number of pages6
Issue number16
StatePublished - Apr 16 2015
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology


Dive into the research topics of 'Lenalidomide in non-Hodgkin lymphoma: Biological perspectives and therapeutic opportunities'. Together they form a unique fingerprint.

Cite this